Anthem Biosciences Reports Audited Consolidated Financial Results for FY26 and Q4FY26
Anthem Biosciences Limited, an innovation-driven Contract Research, Development and Manufacturing Organization (CRDMO), announced its Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.The company reported significant growth across key segments, with consolidated revenue from operations for the full year reaching ₹21,243 Mn. For the quarter ended March 31, 2026, consolidated revenue stood at ₹6,109 Mn.Financial Highlights: FY26 vs. Q4FY26
The financial performance data for the full year (FY26) and the fourth quarter (Q4FY26) showed robust growth compared to the previous year (FY25 and Q4FY25).Particulars (₹...